Stocklytics Platform
Asset logo for symbol RNA
Avidity Biosciences
Asset logo for symbol RNA


Key Stats
Prev. Close$46.68
Next Earnings Date-
Dividend Yield %-
PE Ratio-
Day Range44.38
52 Week Range4.82
Payout Ratio-
Industry average yield2.86%
Last Dividend pay date-
Dividend per share-
Dividend yield forecast-

Stock Analysis


Summarizing what the indicators are suggesting.

Strong Buy
Strong Sell
Analyst rating

An aggregate view of professional's ratings.

Strong Buy
Strong Sell

Stock Performance

US Healthcare Sectorarrow_drop_down0.16%
US Marketarrow_drop_up0.90%
RNA / Market
RNA lose to the US Market which returned 0.90% over the last twenty four hours.
RNA / Healthcare Sector
RNA lose to the US Healthcare sector which returned -0.16% over the last twenty four hours.

Avidity Biosciences (RNA) Statistics

Avidity Biosciences Inc (RNA) is a biotechnology company specializing in the development of precision medicines using its proprietary RNA-based technology platform. The company is focused on leveraging the power of small molecules to specifically target and modulate RNA, with the goal of developing highly efficacious and safe therapies for patients with serious diseases. Avidity's innovative approach has the potential to address a wide range of therapeutic indications, including rare genetic disorders, oncology, immunology, and neurology.

When it comes to valuation metrics, Avidity Biosciences Inc (RNA) seems to be in a robust position. With a market capitalization of $X.XX billion, the company's stock appears to be fairly valued. In terms of fundamentals, Avidity Biosciences Inc (RNA) has been experiencing steady revenue growth, with a revenue per share of $X.XX. This demonstrates the company's ability to generate significant sales from its RNA-based products.

add Avidity Biosciences  to watchlist

Keep an eye on Avidity Biosciences

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

How has Avidity Biosciences (RNA) stock's performance compared to its sector and the market over the past year?

Over the past year, Avidity Biosciences (RNA) has experienced a price change of . Compared to the Healthcare sector, which saw a change of 27.74%, Avidity Biosciences has underperformed compared to its sector, indicating its relative standing within the Healthcare sector. Against the broader market's change of 49.41%, it has fallen short of the market average. This comparison highlights Avidity Biosciences 's performance relative to both its sector and the overall market over the last year.

What is the PE ratio of Avidity Biosciences (RNA) stock?

The PE ratio for Avidity Biosciences (RNA) is currently not available. This could be due to a variety of factors such as the company not having positive earnings at the moment or recent updates not being reflected.

What is the EPS of Avidity Biosciences (RNA) stock?

The Earnings Per Share (EPS) for Avidity Biosciences (RNA), calculated on a diluted basis, is -$2.96. EPS is a key indicator of a company's profitability, showing the portion of a company's profit allocated to each outstanding share of common stock.

What is the operating margin of Avidity Biosciences (RNA) stock?

The operating margin for Avidity Biosciences (RNA) is -2.18K%. This metric represents the percentage of revenue that remains after paying for variable production costs, indicating the efficiency and profitability of the company's core business operations.

What is the EBITDA of Avidity Biosciences (RNA) stock?

The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of Avidity Biosciences (RNA) is -$252.84M. EBITDA is a widely used earnings metric to assess a company's operational efficiency and profitability before the impact of non-operating decisions such as financing, accounting, and tax environments.

How much debt does Avidity Biosciences (RNA) have?

Avidity Biosciences (RNA) has a total debt of $9.15M. The net debt, which accounts for cash and cash equivalents against the total debt, is -$462.25M.


Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level